New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy
ImaginAb Inc. has announced a poster presentation at AACR 2023 on April 18, 2023, highlighting an independent analysis by AstraZeneca based on the IAB-CD8-201 'iCorrelate' Phase II study. The analysis indicates that CD8 ImmunoPET/CT imaging can differentiate responders from non-responders in patients undergoing immune checkpoint blockade therapy.
The findings suggest a lesion scoring system can provide response evaluations at a median of 35 days, significantly earlier than the 105 days typically required by RECIST. Additionally, it underscores the importance of combining CD8 ImmunoPET and CT measurements for accurate assessments.
ImaginAb’s CD8 ImmunoPET™ aims to enhance drug response evaluations and optimize treatment strategies in immunotherapy trials.
- Independent analysis shows potential for CD8 ImmunoPET/CT to distinguish treatment responders, enhancing clinical decision-making.
- Response evaluation can be achieved at a median of 35 days, significantly faster than conventional methods.
- None.
- Adopting a lesion scoring system based on measurements from CD8 ImmunoPET/CT stratification is achieved at a median of 35 days, providing response evaluation at a much earlier time point than RECIST where the median best is 105 days.
- Complementarity of CD8 ImmunoPET and CT measurements, as shown by the substantial reduction in discriminative power between the two cohorts when restricting the lesion scoring system to either the CD8 ImmunoPET uptake or CT measurements alone.
"These results of the independent data analysis highlight the potential for CD8 ImmunoPET/CT to be used as a robust decision maker in investigational immunotherapy trials for early assessment of pharmacodynamic response, which may help establish drug mechanism of action, prioritization of indications/tumor types, dose optimization and escalation, and to evaluate efficacy of mono vs combination therapies."
Potdevin, G | A first assessment of CD8-PET/CT with 89-Zr-Crefmirlimab as predictive biomarker for response to standard of care immunotherapy in patients with solid tumors. | Abstract # 3577/2 Poster PET, MRI, and CT Imaging |
About
A clinical stage, revenue-generating global biotechnology company developing next-generation imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody platforms. The lead candidate, CD8 ImmunoPET™, is currently in Phase II clinical trials and has been licensed by pharmaceutical and biotech companies for use in immunotherapy clinical trials.
About CD8 ImmunoPET™
An 89Zr-labelled minibody designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging. This method is currently being researched to determine whether it may be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.
More information: https://imaginab.com/products/cd8-immunopet/
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-analysis-of-phase-ii-data-at-aacr-assesses-imaginabs-investigational-cd8-immunopet-technologys-ability-to-predict-response-in-immunotherapy-301797289.html
SOURCE
FAQ
What are the findings from AstraZeneca's analysis of the IAB-CD8-201 study presented at AACR 2023?
What is the significance of CD8 ImmunoPET/CT imaging in cancer treatment?
When and where was the AACR 2023 presentation made regarding ImaginAb's technology?
What is the main benefit of using CD8 ImmunoPET compared to traditional assessment methods?
